<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>62(1)</volume><submitter>Dong X</submitter><funding>Clinical and Experimental Research</funding><pubmed_abstract>&lt;h4>Context&lt;/h4>Yi-Shen-Hua-Shi (YSHS) is a traditional Chinese medicine that treats chronic kidney disease (CKD). However, its efficacy in reducing proteinuria and underlying mechanisms is unknown.&lt;h4>Objective&lt;/h4>This single-center randomized controlled trial explored whether YSHS could improve proteinuria and modulate the gut microbiota.&lt;h4>Materials and methods&lt;/h4>120 CKD patients were enrolled and randomized to receive the renin-angiotensin-aldosterone system (RAAS) inhibitor plus YSHS (&lt;i>n&lt;/i> = 56) or RAAS inhibitor (&lt;i>n&lt;/i> = 47) alone for 4 months, and 103 patients completed the study. We collected baseline and follow-up fecal samples and clinical outcomes from participants. Total bacterial DNA was extracted, and the fecal microbiome was analyzed using bioinformatics.&lt;h4>Resul</pubmed_abstract><journal>Pharmaceutical biology</journal><pagination>356-366</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11085992</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Yi-Shen-Hua-Shi regulates intestinal microbiota dysbiosis and protects against proteinuria in patients with chronic kidney disease: a randomized controlled study.</pubmed_title><pmcid>PMC11085992</pmcid><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Dong X</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Fu W</pubmed_authors><pubmed_authors>Jia L</pubmed_authors><pubmed_authors>Zhang A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Yi-Shen-Hua-Shi regulates intestinal microbiota dysbiosis and protects against proteinuria in patients with chronic kidney disease: a randomized controlled study.</name><description>&lt;h4>Context&lt;/h4>Yi-Shen-Hua-Shi (YSHS) is a traditional Chinese medicine that treats chronic kidney disease (CKD). However, its efficacy in reducing proteinuria and underlying mechanisms is unknown.&lt;h4>Objective&lt;/h4>This single-center randomized controlled trial explored whether YSHS could improve proteinuria and modulate the gut microbiota.&lt;h4>Materials and methods&lt;/h4>120 CKD patients were enrolled and randomized to receive the renin-angiotensin-aldosterone system (RAAS) inhibitor plus YSHS (&lt;i>n&lt;/i> = 56) or RAAS inhibitor (&lt;i>n&lt;/i> = 47) alone for 4 months, and 103 patients completed the study. We collected baseline and follow-up fecal samples and clinical outcomes from participants. Total bacterial DNA was extracted, and the fecal microbiome was analyzed using bioinformatics.&lt;h4>Resul</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2026-06-03T04:26:39.309Z</modification><creation>2026-04-24T03:09:38.372Z</creation></dates><accession>S-EPMC11085992</accession><cross_references><pubmed>38720666</pubmed><doi>10.1080/13880209.2024.2345080</doi></cross_references></HashMap>